AI-generated research brief — verify at source
Bellmunt Risk Score Validated as Independent Prognostic Tool Across mCRPC Treatment Lines
A three-point clinical scoring system predicted overall survival with striking discrimination in two large phase 3 trial cohorts: men with metastatic castration-resistant prostate cancer scoring 3 on the Bellmunt Risk Score faced more than eight times the mortality hazard of those scoring 0 in the first-line setting (AHR 8.29, 95% CI 2.57–26.78). The score’s consistent performance across both treatment-naïve and post-docetaxel populations strengthens confidence in its broad applicability.
What Was Studied
Researchers sought to determine whether the Bellmunt Risk Score (BRS), originally developed in the urothelial cancer context and later adapted for prostate cancer, could reliably stratify prognosis in men with metastatic castration-resistant prostate cancer (mCRPC). Because mCRPC follows a highly variable clinical trajectory, a validated and easy-to-apply prognostic tool could meaningfully support treatment planning and clinician-patient discussions about expected outcomes.
How It Was Studied
This was a post hoc prognostic analysis drawing on participant-level data from two international, multicenter phase 3 randomized clinical trials. The ACIS trial, which enrolled 678 evaluable men in the first-line setting between December 2014 and August 2016, contributed a cohort with a median follow-up of 54.8 months (IQR, 51.5–58.4 months). The ELM-PC-5 trial, enrolling 1,078 evaluable men in the post-docetaxel setting between October 2010 and February 2013, had a shorter median follow-up of 10.7 months (IQR, 0.4–27.1 months). Together, the analysis covered 1,756 participants. The BRS was calculated at baseline by assigning one point each for: an ECOG Performance Status score of 1 or higher, hemoglobin below 10 g/dL, and the presence of liver metastases, yielding scores ranging from 0 to 3. Primary outcomes were overall survival (OS) and radiographic progression-free survival, evaluated using Kaplan-Meier methods and multivariable Cox proportional hazards regression.
What Was Observed
- Stepwise survival decline with rising BRS in first-line mCRPC: In the ACIS cohort, median OS fell from 42.2 months (95% CI, 35.7–46.7) at BRS 0 to just 9.1 months (95% CI, 3.7–not reached) at BRS 3. The adjusted hazard for death rose progressively — roughly 37% higher at BRS 1 (AHR 1.37, 95% CI 1.12–1.67), about 2.6-fold higher at BRS 2 (AHR 2.64, 95% CI 1.89–3.69), and more than eightfold higher at BRS 3 (AHR 8.29, 95% CI 2.57–26.78) — each relative to BRS 0.
- Consistent gradient confirmed in the post-docetaxel setting: In the ELM-PC-5 cohort, median OS dropped from 23.0 months (95% CI, 21.5–not reached) at BRS 0 to 3.2 months (95% CI, 1.4–8.6) at BRS 3. Adjusted hazard ratios followed a similar pattern: about 65% higher risk at BRS 1 (AHR 1.65, 95% CI 1.31–2.07), nearly threefold at BRS 2 (AHR 2.93, 95% CI 2.22–3.87), and more than fourfold at BRS 3 (AHR 4.43, 95% CI 2.65–7.40).
- BRS retained independent prognostic value after multivariable adjustment: Across all models incorporating other clinical variables, the BRS remained a statistically robust and independent predictor of both overall survival and radiographic progression-free survival in both cohorts.
Why This Matters
The validation of a simple, three-variable score across two distinct treatment lines addresses a genuine gap in mCRPC prognostication, where more complex multi-biomarker tools may be impractical in routine settings. The BRS relies entirely on readily available clinical parameters — performance status, hemoglobin, and imaging findings — requiring no specialized assays. Establishing its cross-cohort reproducibility strengthens the evidence base for incorporating it into clinical trial stratification and standardized outcome frameworks.
How to Read This Result
Because this was a post hoc analysis of trial populations rather than a prospectively designed validation study, residual selection bias and differences in follow-up duration between cohorts should temper certainty, particularly for the BRS 3 group, where confidence intervals were wide.
Limitations
The abstract does not explicitly report study limitations.